%20LIMITED%20-%2068276%2022-Dec-2008_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
22.12.2008 |
IDENTIFICATION DETAILS
|
Name : |
POLYFINE CHEMPHARMA (PVT) LIMITED |
|
|
|
|
Registered Office : |
51, |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1991 |
|
|
|
|
Com. Reg. No.: |
P-00818/19910906 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture and
Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
POLYFINE CHEMPHARMA (PVT) LIMITED
Full Address
|
Registered Address & Factory |
|
51, |
|
Tel |
92 (91) 5814937, 5812756 |
|
Fax |
92 (91) 5814938 |
|
|
Short Description Of Business
|
Nature of Business |
Manufacture & Marketing
of Pharmaceutical Products |
|
Year Established |
1991 |
|
Registration # |
P-00818/19910906 |
Branches
None
Auditors
Munawar Associates
(Chartered Accountants)
Legal Status
Subject Company was established as a Private Limited Company in 1991
|
Authorized Capital |
Rs. 10,000,000/-
divided into 100,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 4,600,000/- divided
into 46,000 shares of Rs. 100/- each |
Details of Chief Executive/
Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Abdul Rasheed Waseem Shehzad Nadeem Shehzad Aleem Shehzad |
Pakistani Pakistani Pakistani Pakistani |
2 - 2 - 2 - 2 - |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
|
Names |
Address |
No. of Shares |
|
Abdul Rasheed Hameeda Begum Naeem Shehzad Mrs. Ishrat Ali Waseem Shehzad Mrs. Sumera Shehzad Nadeem Shehzad Mrs. Uzma Nadeem Saleem Shehzad Mrs. Shabnam Shehzad Azeem Shehzad Aleem Shehzad Naseem Shehzad |
2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - |
1,740 6,940 3,002 1,666 4,366 1,500 4,006 1,666 4,460 1,666 4,996 4,996 4,996 |
Associates
A. Subsidiary
None
B. Associated Companies
- Do -
Products / Services
Manufacture & marketing
of Pharmaceutical Products. Their brand names are Alfavit, Allorat, Ceframed,
Ceftrex, Chloroquine, Chlorpheniramine, Ciprofine, Clavumox, Clonatril,
Cromosol, Devinate, Divirat, Dixigram, Erythromycin, Expodox, Fazim, Fendic,
Fenmol, Flavogin, Flinox, Flogesic, Flu-fine, Flucare, Flurofen, Furazolidone,
Hexalon, Klarifine, Leflocin, Medinol, Metronidazole, Migranil, Milosol,
Naloroptic, Optibram, Paracetamol, Perill, Pirental, Piroflam, Polyclox,
Polygenta, Polylact, Polytax, Polytran, Polyzide, Promethazine, Rorocin,
Silzolin, Simtas, Sterifrin, Sulfadar, Thelmox, Tricosten
Number of Employees
67
Trade Suppliers (Foreign)
TAURUS CHEMICALS,
NORTH CHINA PHARMACEUTICAL GROUP CORP,
Annual Production Volume
The capacity and production of the company’s plant is indeterminable as it involves varying processes of manufacture.
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2006 – 2007 |
40,000,000/- (Estimated) |
Distributors Network
Mainly in
Bankers
(1) United Bank
Limited,
(2) Habib Bank
Limited,
(3) Habib
Metropolitan Bank Limited,
Memberships
Sarhad Chamber of Commerce & Industry.(SCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 79.00 |
|
|
1 |
Rs. 119.10 |
|
Euro |
1 |
Rs. 110.60 |
Comments
Subject Company was established in 1991 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms & conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.47.39 |
|
|
1 |
Rs.70.65 |
|
Euro |
1 |
Rs.66.33 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)